Defective levels of both circulating dendritic cells and T-regulatory cells correlate with risk of recurrence in cutaneous melanoma

被引:8
作者
Tucci, M. [1 ]
Stucci, L. S. [1 ]
Mannavola, F. [1 ]
Passarelli, A. [1 ]
D'Oronzo, S. [1 ]
Lospalluti, L. [2 ]
Giudice, G. [3 ]
Silvestris, F. [1 ]
机构
[1] Univ Bari Aldo Moro, Dept Biomed Sci & Clin Oncol, Sect Oncol, Pza Giulio Cesare 11, I-70124 Bari, Italy
[2] Univ Bari Aldo Moro, Dept Biomed Sci & Clin Oncol, Sect Dermatol, Bari, Italy
[3] Univ Bari Aldo Moro, Dept Emergency & Organ Transplantat, Sect Plast & Reconstruct Surg, Bari, Italy
关键词
Melanoma; Dendritic cells; T-regulatory cells; Immune system; LYMPH-NODE DISSECTION; BIOPSY; LYMPHOCYTES; GENERATION; MONOCYTES; S-100B;
D O I
10.1007/s12094-018-1993-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundImmune markers in the peripheral blood of melanoma patients provide useful information for clinical management although there is poor consensus on circulating cells which could putatively reflect the disease activity and play a prognostic role. Here, we investigated both dendritic cells (DCs) and T-regulatory cells (Tregs).MethodsThe number of DC subsets as myeloid (m) and plasmacytoid was measured by flowcytometry in 113 melanoma patients in different clinical stages and correlated with the disease activity to evaluate the recurrence free survival (RFS) calculated as difference between baseline and post-surgical values in relation to the criteria for the melanoma staging, as primary tumor removal, sentinel lymph node biopsy and completion of lymph node dissection.ResultsCirculating mDC levels were significantly lower in metastatic melanoma than in other stages and inversely correlated to Treg values while both populations were similarly expressed in inactive disease at stage I-III. Furthermore, the levels of these cells after melanoma removal were apparently related to the disease activity since their persistent defect reflected high risk of recurrence and reduced the RFS.ConclusionsThis work highlighted the role of immune cell measurement for the management of melanoma activity and the identification of patients at potential risk of recurrence based on the mDC ratio.
引用
收藏
页码:845 / 854
页数:10
相关论文
共 36 条
[1]   Tumour-derived prostaglandin E2 and transforming growth factor-β synergize to inhibit plasmacytoid dendritic cell-derived interferon-α [J].
Bekeredjian-Ding, Isabelle ;
Schafer, Meike ;
Hartmann, Evelyn ;
Pries, Ralph ;
Parcina, Marijo ;
Schneider, Philip ;
Giese, Thomas ;
Endres, Stefan ;
Wollenberg, Barbara ;
Hartmann, Gunther .
IMMUNOLOGY, 2009, 128 (03) :439-450
[2]   Dendritic Cell-Based Immunotherapy: State of the Art and Beyond [J].
Bol, Kalijn F. ;
Schreibelt, Gerty ;
Gerritsen, Winald R. ;
de Vries, I. Jolanda M. ;
Figdor, Carl G. .
CLINICAL CANCER RESEARCH, 2016, 22 (08) :1897-1906
[3]   Characterization of Circulating Dendritic Cells in Melanoma: Role of CCR6 in Plasmacytoid Dendritic Cell Recruitment to the Tumor [J].
Charles, Julie ;
Di Domizio, Jeremy ;
Salameire, Dimitri ;
Bendriss-Vermare, Nathalie ;
Aspord, Caroline ;
Muhammad, Ramzan ;
Lefebvre, Christine ;
Plumas, Joel ;
Leccia, Marie-Therese ;
Chaperot, Laurence .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2010, 130 (06) :1646-1656
[4]   Characterization of the in vivo immune network of IDO, tryptophan metabolism, PD-L1, and CTLA-4 in circulating immune cells in melanoma [J].
Chevolet, I. ;
Speeckaert, R. ;
Schreuer, M. ;
Neyns, B. ;
Krysko, O. ;
Bachert, C. ;
Hennart, B. ;
Allorge, D. ;
van Geel, N. ;
Van Gele, M. ;
Brochez, L. .
ONCOIMMUNOLOGY, 2015, 4 (03) :1-8
[5]   Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma [J].
Chevolet, Ines ;
Speeckaert, Reinhart ;
Schreuer, Max ;
Neyns, Bart ;
Krysko, Olga ;
Bachert, Claus ;
Van Gele, Mireille ;
van Geel, Nanja ;
Brochez, Lieve .
JOURNAL OF TRANSLATIONAL MEDICINE, 2015, 13
[6]   A prediction tool incorporating the biomarker S-100B for patient selection for completion lymph node dissection in stage III melanoma [J].
Damude, S. ;
Wevers, K. P. ;
Murali, R. ;
Kruijff, S. ;
Hoekstra, H. J. ;
Bastiaannet, E. .
EJSO, 2017, 43 (09) :1753-1759
[7]   The predictive power of serum S-100B for non-sentinel node positivity in melanoma patients [J].
Damude, S. ;
Hoekstra, H. J. ;
Bastiaannet, E. ;
Kobold, A. C. Muller ;
Kruijff, S. ;
Wevers, K. P. .
EJSO, 2016, 42 (04) :545-551
[8]   Plasmacytoid Dendritic Cells in Melanoma: Can We Revert Bad into Good? [J].
Di Domizio, Jeremy ;
Demaria, Olivier ;
Gilliet, Michel .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2014, 134 (07) :1797-1800
[9]   Numerical defect of circulating dendritic cell subsets and defective dendritic cell generation from monocytes of patients with advanced melanoma [J].
Failli, Alessandra ;
Legitimo, Annalisa ;
Orisini, Giulia ;
Romanini, Antonella ;
Consolini, Rita .
CANCER LETTERS, 2013, 337 (02) :184-192
[10]   World-Wide Immunoscore Task Force: meeting report from the "Melanoma Bridge", Napoli, November 30th-December 3rd, 2016 [J].
Galon, Jerome ;
Lugli, Alessandro ;
Bifulco, Carlo ;
Pages, Franck ;
Masucci, Giuseppe ;
Marincola, Francesco M. ;
Ascierto, Paolo A. .
JOURNAL OF TRANSLATIONAL MEDICINE, 2017, 15